775 related articles for article (PubMed ID: 27520560)
41. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping.
Rao J; Sinn M; Pelzer U; Riess H; Oettle H; Demir IE; Friess H; Jäger C; Steiger K; Muckenhuber A
J Pathol Clin Res; 2024 May; 10(3):e12377. PubMed ID: 38750616
[TBL] [Abstract][Full Text] [Related]
42. [Expression of B cell transposition gene 3 in pancreatic ductal adenocarcinoma and its prognostic value].
Chen J; Zhou ZC; Liu WB; Wang J; Chen XJ; Shen YY; Zhong ZX
Zhonghua Wai Ke Za Zhi; 2017 Nov; 55(11):863-867. PubMed ID: 29136736
[No Abstract] [Full Text] [Related]
43. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
[TBL] [Abstract][Full Text] [Related]
44. Hepatocyte nuclear factor 1A (HNF1A) as a possible tumor suppressor in pancreatic cancer.
Luo Z; Li Y; Wang H; Fleming J; Li M; Kang Y; Zhang R; Li D
PLoS One; 2015; 10(3):e0121082. PubMed ID: 25793983
[TBL] [Abstract][Full Text] [Related]
45. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
46. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
47. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.
Aichler M; Seiler C; Tost M; Siveke J; Mazur PK; Da Silva-Buttkus P; Bartsch DK; Langer P; Chiblak S; Dürr A; Höfler H; Klöppel G; Müller-Decker K; Brielmeier M; Esposito I
J Pathol; 2012 Apr; 226(5):723-34. PubMed ID: 21984419
[TBL] [Abstract][Full Text] [Related]
48. HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1.
Xia R; Hu C; Ye Y; Zhang X; Li T; He R; Zheng S; Wen X; Chen R
Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36825600
[TBL] [Abstract][Full Text] [Related]
49. Integrated analysis of mRNA and miRNA expression profiles in pancreatic ductal adenocarcinoma.
Sun H; Zhao L; Pan K; Zhang Z; Zhou M; Cao G
Oncol Rep; 2017 May; 37(5):2779-2786. PubMed ID: 28339085
[TBL] [Abstract][Full Text] [Related]
50. LncRNA co-expression network analysis reveals novel biomarkers for pancreatic cancer.
Giulietti M; Righetti A; Principato G; Piva F
Carcinogenesis; 2018 Jul; 39(8):1016-1025. PubMed ID: 29796634
[TBL] [Abstract][Full Text] [Related]
51. Orchestrating a biomarker panel with lncRNAs and mRNAs for predicting survival in pancreatic ductal adenocarcinoma.
Wu Y; Wei J; Ming Y; Chen Z; Yu J; Mao R; Chen H; Zhou G; Fan Y
J Cell Biochem; 2018 Sep; 119(9):7696-7706. PubMed ID: 29923223
[TBL] [Abstract][Full Text] [Related]
52. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens.
Rasmussen LG; Verbeke CS; Sørensen MD; Pfeiffer P; Tan Q; Mortensen MB; Fristrup C; Detlefsen S
Pancreatology; 2021 Apr; 21(3):530-543. PubMed ID: 33637450
[TBL] [Abstract][Full Text] [Related]
53. Circular RNA Expression Profile of Pancreatic Ductal Adenocarcinoma Revealed by Microarray.
Li H; Hao X; Wang H; Liu Z; He Y; Pu M; Zhang H; Yu H; Duan J; Qu S
Cell Physiol Biochem; 2016; 40(6):1334-1344. PubMed ID: 27997903
[TBL] [Abstract][Full Text] [Related]
54. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
55. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma.
Xiao Y; Zhang B; Cloyd JM; Xu G; Du S; Mao Y; Pawlik TM
Surg Oncol; 2022 Sep; 44():101849. PubMed ID: 36116415
[TBL] [Abstract][Full Text] [Related]
56. Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome.
N Kalimuthu S; Wilson GW; Grant RC; Seto M; O'Kane G; Vajpeyi R; Notta F; Gallinger S; Chetty R
Gut; 2020 Feb; 69(2):317-328. PubMed ID: 31201285
[TBL] [Abstract][Full Text] [Related]
57. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
Kandimalla R; Shimura T; Mallik S; Sonohara F; Tsai S; Evans DB; Kim SC; Baba H; Kodera Y; Von Hoff D; Chen X; Goel A
Ann Surg; 2022 Jan; 275(1):e229-e237. PubMed ID: 32398486
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA modulated networks of adaptive and innate immune response in pancreatic ductal adenocarcinoma.
Felix TF; Lopez Lapa RM; de Carvalho M; Bertoni N; Tokar T; Oliveira RA; M Rodrigues MA; Hasimoto CN; Oliveira WK; Pelafsky L; Spadella CT; Llanos JC; F Silva G; Lam WL; Rogatto SR; Amorim LS; Drigo SA; Carvalho RF; Reis PP
PLoS One; 2019; 14(5):e0217421. PubMed ID: 31150430
[TBL] [Abstract][Full Text] [Related]
59. Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma.
Chen DT; Davis-Yadley AH; Huang PY; Husain K; Centeno BA; Permuth-Wey J; Pimiento JM; Malafa M
PLoS One; 2015; 10(8):e0133562. PubMed ID: 26247463
[TBL] [Abstract][Full Text] [Related]
60. Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers.
Mantini G; Vallés AM; Le Large TYS; Capula M; Funel N; Pham TV; Piersma SR; Kazemier G; Bijlsma MF; Giovannetti E; Jimenez CR
Cell Oncol (Dordr); 2020 Dec; 43(6):1147-1159. PubMed ID: 32860207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]